Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California with a unique ability to rapidly engineer, optimize and manufacture superior, high-fidelity vaccines at scale. We do this by re-engineering how highly complex vaccines are made, using advanced chemistry and modern synthetic techniques - including the XpressCF cell-free protein synthesis platform - to create difficult-to-make proteins that deliver enhanced immunological benefits. Our lead clinical candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine (PCV) to treat invasive pneumococcal disease and pneumonia currently being investigated in a Phase 1/2 proof-of-concept study in adults. We are pursuing a clear strategy for our PCV franchise, which leverages a known regulatory pathway established by already approved PCVs.
We are preparing to deliver PCVs at a global scale upon regulatory approval through a strategic supply relationship with Lonza, one of the world’s leading contract manufacturers of complex biologics.
In addition, our pipeline includes VAX-XP, an even broader-spectrum PCV, and other preclinical programs targeting Group A Strep and periodontitis.
At Vaxcyte, we are driven to protect humankind by eliminating invasive bacterial infections that have serious and costly health consequences when left unchecked. Pneumococcal disease, Group A Strep and periodontitis are just the beginning. Our path to success is clear and well-defined, and Vaxcyte is set up to go the distance.
At Vaxcyte, we are driven by our:
To prevent or treat infections caused by bacterial diseases such as pneumococcal disease, Group A Strep and periodontitis.
Sense of Urgency
Bacterial infections remain one of the greatest public health challenges of the 21st century.
Re-engineering the way complex vaccines are
made by leveraging our advanced chemistry platform that goes beyond conventional vaccine development approaches.
We are on a global mission to engineer high-fidelity vaccines that protect humankind from the consequences of bacterial diseases.
Despite renewed interest in vaccine innovation, bacterial infectious diseases have not historically received adequate attention. The global incidence of pneumococcal disease remains high, driven in part by emerging serotypes not covered by currently available vaccines. Our site-specific conjugation technology allows us to engineer broader-spectrum pneumococcal conjugate vaccines (PCVs) that we believe may enable our PCV franchise to surpass the coverage of other pneumococcal vaccines and provide greater disease protection, while maintaining effectiveness.